SONN News and Press, Sonnet BioTherapeutics Holdings Inc. From 05/03/24

2024-05-03 13:17:33 ET More on Sonnet BioTherapeutics Seeking Alpha’s Quant Rating on Sonnet BioTherapeutics Historical earnings data for Sonnet BioTherapeutics Financial information for Sonnet BioTherapeutics Read the full article on Seeking Alpha ...

Minneapolis, Minnesota--(Newsfile Corp. - May 3, 2024) - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologic drugs, will be participating in the EF Hutton Annual Global Conference, which will take place on May 15, 2024 at The P...

PRINCETON, NJ / ACCESSWIRE / March 19, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that preclinical data and clinical trial design from the study of SON-080 (rec...

2024-03-12 08:28:49 ET More on Pre-market losers & stocks. Renalytix approached by potential buyer, stock rallies 28% Renalytix surges after Medicare draft decision on lead product Seeking Alpha’s Quant Rating on ASLAN Pharmaceuticals Historical ea...

Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON‑080 was reviewed by the study's Data Safety Monitoring Board (DSMB) The adverse event profile and tolerability of SON-080 was consistent with data from previous IL-6 candidates, meeting the Phase...

PRINCETON, NJ / ACCESSWIRE / February 29, 2024 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today the publication of clinical data on SON-1010 in Frontiers in Immunology . SON-1010, Sonnet's lea...

2024-02-14 07:50:48 ET More on Sonnet BioTherapeutics Seeking Alpha’s Quant Rating on Sonnet BioTherapeutics Historical earnings data for Sonnet BioTherapeutics Financial information for Sonnet BioTherapeutics Read the full article on Seeking Alpha ...

2024-02-14 07:37:32 ET More on Sonnet BioTherapeutics Seeking Alpha’s Quant Rating on Sonnet BioTherapeutics Historical earnings data for Sonnet BioTherapeutics Financial information for Sonnet BioTherapeutics Read the full article on Seeking Alpha ...

Successfully raised approximately $4.55 million in gross proceeds through an underwritten public offering Extensive preclinical data on SON-1210 published in Frontiers in Immunology Received approval and executed agreement to sell New Jersey state net operating losses (NOLs) for expecte...

Verde Clean Fuels Inc. (VGAS) is expected to report for Q4 2023 Pioneer Bancorp Inc. (PBFS) is expected to report for Q2 2024 Equity Commonwealth of Beneficial Interest (EQC) is expected to report $0.27 for Q4 2023 monday.com Ltd. (MNDY) is expected to report $-0.31 for Q4 2023 As...